MEN1 and multiple endocrine neoplasia type 1: This is further supported by the LARO-MEN1 study, a prospective and non-comparative trial, which assessed the efficacy of SSAs in MEN1 syndrome-associated PanNEN, highlighting their role in stabilizing disease even in hereditary conditions.